Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Dyadic International, Inc. Dyadic Expands Global Presence with Participation in Key Industry Events October 09, 2024 From Dyadic International, Inc. Via GlobeNewswire Tickers DYAI Dyadic Provides Alternative Proteins Business Update and Announces Attendance at Bioprocess International Conference September 23, 2024 From Dyadic International, Inc. Via GlobeNewswire Tickers DYAI Dyadic International, Inc. and Proliant Health and Biologicals announce Recombinant Albumin Development and Commercialization Partnership June 28, 2024 From Dyadic International, Inc. Via GlobeNewswire Tickers DYAI Dyadic to Attend Industry Events in June May 30, 2024 From Dyadic International, Inc. Via GlobeNewswire Tickers DYAI Dyadic to Attend Industry and Investor Events in May May 08, 2024 From Dyadic International, Inc. Via GlobeNewswire Tickers DYAI Dyadic to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024 April 30, 2024 From Dyadic International, Inc. Via GlobeNewswire Tickers DYAI Dyadic Announces Change in Board and Management Leadership Roles March 28, 2024 From Dyadic International, Inc. Via GlobeNewswire Tickers DYAI Dyadic to Attend Industry Events in April March 27, 2024 From Dyadic International, Inc. Via GlobeNewswire Tickers DYAI Dyadic Announces Publication of C1 Monoclonal Antibody in Nonhuman Primate Study in Nature Communications March 26, 2024 From Dyadic International, Inc. Via GlobeNewswire Tickers DYAI Dyadic to Attend Future Food Tech Event March 21 – 22, 2024 in San Francisco, California March 21, 2024 From Dyadic International, Inc. Via GlobeNewswire Tickers DYAI Dyadic to Report Full Year 2023 Financial Results and Host Conference call on Thursday, March 28, 2024 March 14, 2024 From Dyadic International, Inc. Via GlobeNewswire Tickers DYAI CORRECTION – Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization March 11, 2024 From Dyadic International, Inc. Via GlobeNewswire Tickers DYAI Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization March 11, 2024 From Dyadic International, Inc. Via GlobeNewswire Tickers DYAI Dyadic to Attend Industry Events in March March 01, 2024 From Dyadic International, Inc. Via GlobeNewswire Tickers DYAI Dyadic Announces Strategic Partnership Agreement to Develop Affordable Rabies Prophylactics and Vaccines Using its Proprietary C1 Cell Microbial Protein Production Platform February 28, 2024 From Dyadic International, Inc. Via GlobeNewswire Tickers DYAI Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions February 21, 2024 From Dyadic International, Inc. Via GlobeNewswire Tickers DYAI Dyadic and Cygnus Technologies Announce Partnership To Provide C1 HCP ELISA Assay to Enhance Quality Assurance in Biomanufacturing February 13, 2024 From Dyadic International, Inc. Via GlobeNewswire Tickers DYAI MRVI Dyadic Announces Research and Development Collaboration Agreement with Global Biopharmaceutical Company February 06, 2024 From Dyadic International, Inc. Via GlobeNewswire Tickers DYAI Dyadic to Attend BIO CEO & Investor Conference and European Industry Events February 01, 2024 From Dyadic International, Inc. Via GlobeNewswire Tickers DYAI Dyadic to Attend J.P. Morgan 42nd Annual Healthcare Conference January 02, 2024 From Dyadic International, Inc. Via GlobeNewswire Tickers DYAI Dyadic Attends Investor Events in December November 30, 2023 From Dyadic International, Inc. Via GlobeNewswire Tickers DYAI Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate November 29, 2023 From Dyadic International, Inc. Via GlobeNewswire Tickers DYAI Dyadic’s C1 Platform to be Used to Produce Vaccines for Humans and Animals in Africa November 20, 2023 From Dyadic International, Inc. Via GlobeNewswire Tickers DYAI Dyadic to Present at Industry Events in November October 30, 2023 From Dyadic International, Inc. Via GlobeNewswire Tickers DYAI Dyadic to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023 October 25, 2023 From Dyadic International, Inc. Via GlobeNewswire Tickers DYAI Dyadic Appoints Doug Pace to Its Executive Leadership Team October 09, 2023 From Dyadic International, Inc. Via GlobeNewswire Tickers DYAI Dyadic’s C1 Platform Selected by the Vaccine and Immunotherapy Center (“VIC”) at Massachusetts General Hospital as Part of VIC’s $5.88 Million Award by U.S. DoD to Develop a Self-Assembling Vaccine (SAV) Platform for Rapid Production of Prophylactic October 05, 2023 From Dyadic International, Inc. Via GlobeNewswire Tickers DYAI Dyadic to Present at Industry and Investor Events in October September 29, 2023 From Dyadic International, Inc. Via GlobeNewswire Tickers DYAI Dyadic and bYoRNA Announce a Collaboration Targeting the Production of Abundant, Low-Cost mRNA From C1-Cells September 26, 2023 From Dyadic International, Inc. Via GlobeNewswire Tickers DYAI Dyadic Announces Development and License Agreement to Commercialize Animal-Free Alternative Proteins Using Dapibus™ September 19, 2023 From Dyadic International, Inc. Via GlobeNewswire Tickers DYAI Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
